Clinical trial · Observational
Proteomics in Small Cell Lung Cancer
Circulating Metabolites and Tumor-derived Extravesicular Proteins in Small Cell Lung Cancer
NCT05623956CI-TRIAL-00085349SCLC-OMICSunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to gather insight into tumor-derived circulating extracellular vesicles-proteins in patients with newly diagnosed small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Identification and validation of protein biomarkers
- timeFrame
- 3 years
- description
- For identification and validation of protein biomarkers both untargeted and targeted proteomics will be performed, including a discovery-based bottom-up mass spectrometry approach and label-free Quantification Nano Liquid Chromatography Tandem Mass Spectrometry (LFQ nLC-MS/MS), enzyme-linked immunosorbent assay (ELISA)-based proteomics, and Western Blot analyses.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written and signed informed consent * Histopathologically and/or cytologically newly-diagnosed SCLC * Measurable disease on CT scans * Eligibility to receive standard chemotherapy consisting of carboplatin and etoposide Exclusion Criteria: * Active biopsy-verified second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ * Prior treatment for any malignant diseases other than non-melanoma skin cancer and cervical carcinoma in situ * Concomitant anticoagulation treatment (acetylsalicylic acid and clopidogrel are allowed) * Treatment with any other investigational agent
References
Publications (0)
Data not yet available
No reference posted for this study.